Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (tumor)

ABSTRACT: Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (tumor)

PROVIDER: PRJNA1001503 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25498605_1.fastq.gz	Fastqsanger.gz
	SRR25498605_2.fastq.gz	Fastqsanger.gz
	SRR25498606_1.fastq.gz	Fastqsanger.gz
	SRR25498606_2.fastq.gz	Fastqsanger.gz
	SRR25498607_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (TCR)

Project description:Immune escape is a prerequisite of tumor growth. We previously described a decline in intratumor activated GZMB+CD8+ T cells and T cell receptor (TCR) clonotype diversity in invasive compared to in situ (DCIS) breast carcinomas implying a role for decreasing TCR diversity in tumor progression. Here, we evaluated peripheral blood TCR clonotype diversity in breast cancer patients diagnosed with DCIS or de novo stage IV disease at different ages. We found that peripheral TCR diversity is associated with clinicopathologic, and peripheral immune status and it correlates with the frequency of CD8+ T cells in DCIS of young patients. These results provide new insights to the role of host immunity and breast cancer development in different aged women.

2024-03-13 | GSE261515 | GEO

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (blood)

2023-11-09 | GSE239933 | GEO

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (tumor)

2023-11-09 | GSE239934 | GEO

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (TCR)

Project description:Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (TCR)

| PRJNA1087365 | ENA

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression

Project description:Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression

| PRJNA1001408 | ENA

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (blood)

Project description:Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression (blood)

| PRJNA1001501 | ENA

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression.

Project description:Immune escape is a prerequisite for tumor growth. We previously described a decline in intratumor activated cytotoxic T cells and T cell receptor (TCR) clonotype diversity in invasive breast carcinomas compared to ductal carcinoma in situ (DCIS), implying a central role of decreasing T cell responses in tumor progression. To determine potential associations between peripheral immunity and breast tumor progression, here, we assessed the peripheral blood TCR clonotype of 485 breast cancer patients diagnosed with either DCIS or de novo stage IV disease at younger (<45) or older (≥45) age. TCR clonotype diversity was significantly lower in older compared to younger breast cancer patients regardless of tumor stage at diagnosis. In the younger age group, TCR-α clonotype diversity was lower in patients diagnosed with de novo stage IV breast cancer compared to those diagnosed with DCIS. In the older age group, DCIS patients with higher TCR-α clonotype diversity were more likely to have a recurrence compared to those with lower diversity. Whole blood transcriptome profiles were distinct depending on the TCR-α Chao1 diversity score. There were more CD8+ T cells and a more active immune environment in DCIS tumors of young patients with higher peripheral blood TCR-α Chao1 diversity than in those with lower diversity. These results provide insights into the role that host immunity plays in breast cancer development across different age groups.

| S-EPMC10710020 | biostudies-literature

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-11-09 | GSE239935 | GEO

Pan-cancer γδ TCR analysis uncovers clonotype diversity and prognostic potential.

Project description:Gamma-delta T cells (γδ T cells) play a crucial role in both innate and adaptive immunity within tumors, yet their presence and prognostic value in cancer remain underexplored. This study presents a large-scale analysis of γδ T cell receptor (γδ TCR) reads from 11,000 tumor samples spanning 33 cancer types, utilizing the TRUST4 algorithm. Our findings reveal extensive diversity in γδ TCR clonality and gene expression, underscoring the potential of γδ T cells as prognostic biomarkers in various cancers. We further demonstrate the utility of TCR gamma (TRG) and delta (TRD) gene expression from standard RNA-sequencing (RNA-seq) data. This comprehensive dataset offers a valuable resource for advancing γδ T cell research, with implications for enhanced immunotherapy approaches or alternative therapeutic strategies. Additionally, our centralized database supports translational research into the therapeutic significance of γδ T cells.

| S-EPMC11513832 | biostudies-literature

Single-cell RNA sequencing on peripheral blood PBMCs from 4T1 mouse model treated with STING agonist deliveredy by PEG biopsy marker does not reveal peripheral T cell clonal expansion.

Project description:To explore whether immune escape could be secondary to a failure of STING agonist to induce T-cell clonality and expansion, we performed single-cell RNA sequencing (scRNAseq) and T-cell receptor sequencing (TCR-seq) on peripheral PBMCs from animals treated with PEG markers with PBS or 100 µg ADU-S100, using the low tumor burden model of 4T1. Cell types were clustered based on gene signature analysis with 9 resultant clusters. We then analyzed the frequency of unique clonotypes that were expanded following PBS versus ADU-S100 treatment. In both groups, most of the cells that had a unique clonotype did not expand, showing a frequency of 1. There were no specific clonotypes that had a frequency over 5, indicating that ADU-S100 treatment of 4T1 mice does not result in peripheral T cell clonal expansion.

2025-04-21 | GSE294846 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data